Unknown

Dataset Information

0

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.


ABSTRACT: KRAS is the most commonly mutated oncogene in human cancer. Most KRAS-mutant cancers depend on sustained expression and signaling of KRAS, thus making it a high-priority therapeutic target. Unfortunately, development of direct small molecule inhibitors of KRAS function has been challenging. An alternative therapeutic strategy for KRAS-mutant malignancies involves targeting codependent vulnerabilities or synthetic lethal partners that are preferentially essential in the setting of oncogenic KRAS. KRAS activates numerous effector pathways that mediate proliferation and survival signals. Moreover, cancer cells must cope with substantial oncogenic stress conferred by mutant KRAS. These oncogenic signaling pathways and compensatory coping mechanisms of KRAS-mutant cancer cells form the basis for synthetic lethal interactions. Here, we review the compendium of previously identified codependencies in KRAS-mutant cancers, including the results of numerous functional genetic screens aimed at identifying KRAS synthetic lethal targets. Importantly, many of these vulnerabilities may represent tractable therapeutic opportunities.

SUBMITTER: Aguirre AJ 

PROVIDER: S-EPMC5990478 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4317830 | BioStudies
1000-01-01 | S-EPMC4015238 | BioStudies
2015-01-01 | S-EPMC4527963 | BioStudies
2020-01-01 | S-EPMC7217969 | BioStudies
2009-01-01 | S-EPMC2783335 | BioStudies
2016-01-01 | S-EPMC5155639 | BioStudies
2019-01-01 | S-EPMC6428690 | BioStudies
1000-01-01 | S-EPMC3411175 | BioStudies
2016-01-01 | S-EPMC5161658 | BioStudies
2019-01-01 | S-EPMC6394693 | BioStudies